|
ATP6V1C1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.2005999485778E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.04810000012279E-07 |
| Normal-vs-Stage2 |
7.419600E-03 |
| Normal-vs-Stage3 |
7.23140003433542E-09 |
| Normal-vs-Stage4 |
1.18210000010777E-07 |
| Stage1-vs-Stage2 |
1.878450E-01 |
| Stage1-vs-Stage3 |
1.885550E-01 |
| Stage1-vs-Stage4 |
1.691830E-01 |
| Stage2-vs-Stage3 |
6.096000E-02 |
| Stage2-vs-Stage4 |
4.618500E-02 |
| Stage3-vs-Stage4 |
7.106600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.5340000904589E-10 |
| Normal-vs-AfricanAmerican |
4.582700E-03 |
| Normal-vs-Asian |
2.219800E-04 |
| Caucasian-vs-AfricanAmerican |
3.126400E-01 |
| Caucasian-vs-Asian |
5.276800E-01 |
| AfricanAmerican-vs-Asian |
6.798200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.11090000823822E-09 |
| Normal-vs-Female |
1.14839999953986E-07 |
| Male-vs-Female |
1.531010E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.63310000003791E-06 |
| Normal-vs-Age(41-60Yrs) |
4.00580002501982E-09 |
| Normal-vs-Age(61-80Yrs) |
3.33419999998252E-06 |
| Normal-vs-Age(81-100Yrs) |
3.160600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.679980E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.165800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.643800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.670800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.060600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.586800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.725800E-01 |
| Classical-VS-Follicular |
2.381000E-01 |
| Classical-VS-Other |
3.129800E-01 |
| Classical-VS-Normal |
7.32899996247482E-09 |
| Tall-VS-Follicular |
6.045700E-02 |
| Tall-VS-Other |
6.152800E-01 |
| Tall-VS-Normal |
6.73249999971759E-07 |
| Follicular-VS-Other |
2.786000E-01 |
| Follicular-VS-Normal |
1.376370E-03 |
| Other-VS-Normal |
3.256100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.75919999970631E-07 |
| Normal-vs-N1 |
8.93690000003389E-07 |
| N0-vs-N1 |
2.706400E-01 |
|
|
